Atorvastatin inhibits osteoclast differentiation by suppressing NF-κB and MAPK signaling during IL-1β-induced osteoclastogenesis
4
조회
0
다운로드
1
인용
0
참고문헌
키워드
초록
Background/Aims: To define the effect of statins on interleukin 1β (IL-1β)-induced osteoclastogenesis and elucidate the underlying mechanisms. Methods: Bone marrow cells were obtained from 5-week-old male ICR (Institute for Cancer Research) mice, and they were cultured to differentiate them into osteoclasts with macrophage colony-stimulating factor and the receptor activator of nuclear factor (NF)-κB ligand in the presence or absence of IL-1β or atorvastatin. The formation of osteoclasts was evaluated by tartrate-resistant acid phosphatase (TRAP) staining and resorption pit assay with dentine slice. The molecular mechanisms of the effects of atorvastatin on osteoclastogenesis were investigated using reverse transcription polymerase chain reaction and immunoblotting for osteoclast specific molecules. Results: Atorvastatin significantly reduced the number of TRAP-positive multinucleated cells as well as the bone resorption area. Atorvastatin also downregulated the expression of the NF of activated T-cell c1 messenger RNA and inhibited the expression of osteoclast-specific genes. A possible underlying mechanism may be that atorvastatin suppresses the degradation of the inhibitors of NF-κB and blocks the activation of the c-Jun N-terminal kinase, extracellular signal-regulated kinase, and p38; thus, implicating the NF-κB and mitogen-activated protein kinases pathway in this process. Conclusions: Atorvastatin is a strong inhibitor of inflammation-induced osteoclastogenesis in inflammatory joint diseases.
Abstract
Background/Aims: To define the effect of statins on interleukin 1β (IL-1β)-induced osteoclastogenesis and elucidate the underlying mechanisms. Methods: Bone marrow cells were obtained from 5-week-old male ICR (Institute for Cancer Research) mice, and they were cultured to differentiate them into osteoclasts with macrophage colony-stimulating factor and the receptor activator of nuclear factor (NF)-κB ligand in the presence or absence of IL-1β or atorvastatin. The formation of osteoclasts was evaluated by tartrate-resistant acid phosphatase (TRAP) staining and resorption pit assay with dentine slice. The molecular mechanisms of the effects of atorvastatin on osteoclastogenesis were investigated using reverse transcription polymerase chain reaction and immunoblotting for osteoclast specific molecules. Results: Atorvastatin significantly reduced the number of TRAP-positive multinucleated cells as well as the bone resorption area. Atorvastatin also downregulated the expression of the NF of activated T-cell c1 messenger RNA and inhibited the expression of osteoclast-specific genes. A possible underlying mechanism may be that atorvastatin suppresses the degradation of the inhibitors of NF-κB and blocks the activation of the c-Jun N-terminal kinase, extracellular signal-regulated kinase, and p38; thus, implicating the NF-κB and mitogen-activated protein kinases pathway in this process. Conclusions: Atorvastatin is a strong inhibitor of inflammation-induced osteoclastogenesis in inflammatory joint diseases.
참고문헌 (39)
- Schett G, "Bone erosion in rheumatoid arthritis: mechanisms, diagnosis and treatment", Nat Rev Rheumatol, 8, pp.656~664 (2012)[DOI]
- Gravallese EM, "Cellular mechanisms and the role of cytokines in bone erosions in rheumatoid arthritis", Arthritis Rheum, 43, pp.2143~2151 (2000)[DOI]
- Suda T, "Modulation of osteoclast differentiation and function by the new members of the tumor necrosis factor receptor and ligand families", Endocr Rev, 20, pp.345~357 (1999)[DOI]
- Hofbauer LC, "The roles of osteoprotegerin and osteoprotegerin ligand in the paracrine regulation of bone resorption", J Bone Miner Res, 15, pp.2~12 (2000)[DOI]
- Yasuda H, "Osteoclast differentiation factor is a ligand for osteoprotegerin", osteoclastogenesis- inhibitory factor and is identical to TRANCE, Proc Natl Acad Sci U S A, pp.1998, 95[DOI]
- Kong YY, "OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis", Nature, 397, pp.315~323 (1999)[DOI]
- Lee ZH, "Signal transduction by receptor activator of nuclear factor kappa B in osteoclasts", Biochem Biophys Res Commun, 305, pp.211~214 (2003)[DOI]
- Teitelbaum SL, "Genetic regulation of osteoclast development and function", Nat Rev Genet, 4, pp.638~649 (2003)[DOI]
- Matsuo K, "Nuclear factor of activated T-cells (NFAT) rescues osteoclastogenesis in precursors lacking c-Fos", J Biol Chem, 279, pp.26475~26480 (2004)[DOI]
- Takayanagi H, "Induction and activation of the transcription factor NFATc1 (NFAT2) integrate RANKL signaling in terminal differentiation of osteoclasts", Dev Cell, 3, pp.889~901 (2002)[DOI]
- Stern RH, "Pharmacodynamics and pharmacokinetic- pharmacodynamic relationships of atorvastatin, an HMG-CoA reductase inhibitor", J Clin Pharmacol, 40, pp.616~623 (2000)[DOI]
- Malhotra HS, "Atorvastatin: an updated review of its pharmacological properties and use in dyslipidaemia", Drugs, 61, pp.1835~1881 (2001)[DOI]
- Pahan K, "Lovastatin and phenylacetate inhibit the induction of nitric oxide synthase and cytokines in rat primary astrocytes, microglia, and macrophages", J Clin Invest, 100, pp.2671~2679 (1997)[DOI]
- Blaschke S, "Anti-inflammatory effects of atorvastatin on peripheral blood mononuclear cells and synovial fibroblasts in rheumatoid arthritis", Scand J Rheumatol, 38, pp.235~239 (2009)[DOI]
- Weitz-Schmidt G, "Statins selectively inhibit leukocyte function antigen-1 by binding to a novel regulatory integrin site", Nat Med, 7, pp.687~692 (2001)[DOI]
- Majima T, "Short-term effects of atorvastatin on bone turnover in male patients with hypercholesterolemia", Endocr J, 54, pp.145~151 (2007)[DOI]
- Nakagawa T, "Autoinhibitory regulation of p73 by delta Np73 to modulate cell survival and death through a p73-specific target element within the delta Np73 promoter", Mol Cell Biol, 22, pp.2575~2585 (2002)[DOI]
- Mbalaviele G, "The role of cadherin in the generation of multinucleated osteoclasts from mononuclear precursors in murine marrow", J Clin Invest, 95, pp.2757~2765 (1995)[DOI]
- Yagi M, "DC-STAMP is essential for cell-cell fusion in osteoclasts and foreign body giant cells", J Exp Med, 202, pp.345~351 (2005)[DOI]
- Verrier S, "ADAM gene expression and regulation during human osteoclast formation", Bone, 35, pp.34~46 (2004)[DOI]
- Garrett IR, "Statins and bone formation", Curr Pharm Des, 7, pp.715~736 (2001)[DOI]
- Mundy G, "Stimulation of bone formation in vitro and in rodents by statins", Science, 286, pp.1946~1949 (1999)[DOI]
- Maritz FJ, "Effect of statins on bone mineral density and bone histomorphometry in rodents", Arterioscler Thromb Vasc Biol, 21, pp.1636~1641 (2001)[DOI]
- Abud-Mendoza C, "Therapy with statins in patients with refractory rheumatic diseases: a preliminary study", Lupus, 12, pp.607~611 (2003)[DOI]
- El-Barbary AM, "Effect of atorvastatin on inflammation and modification of vascular risk factors in rheumatoid arthritis", J Rheumatol, 38, pp.229~235 (2011)[DOI]
- McCarey DW, "Trial of Atorvastatin in Rheumatoid Arthritis (TARA): double- blind, randomised placebo-controlled trial", Lancet, 363, pp.2015~2021 (2004)[DOI]
- Kim JY, "Atorvastatin inhibits osteoclastogenesis by decreasing the expression of RANKL in the synoviocytes of rheumatoid arthritis", Arthritis Res Ther, 14, pp.R187~ (2012)[DOI]
- Machold KP, "Very recent onset rheumatoid arthritis: clinical and serological patient characteristics associated with radiographic progression over the first years of disease", Rheumatology (Oxford), 46, pp.342~349 (2007)
- Gitter BD, "Characteristics of human synovial fibroblast activation by IL-1 beta and TNF alpha", Immunology, 66, pp.196~200 (1989)
- Jules J, "Molecular basis of requirement of receptor activator of nuclear factor <TEX>${\kappa}B$<", TEX> signaling for interleukin 1-mediated osteoclastogenesis, 2012, pp.287, 15728~15738
- Asagiri M, "Autoamplification of NFATc1 expression determines its essential role in bone homeostasis", J Exp Med, 202, pp.1261~1269 (2005)[DOI]
- Partington GA, "1 interactions with the tartrate-resistant acid phosphatase gene promoter during osteoclast differentiation", Bone, 34, pp.237~245 (2004)[DOI]
- Soysa NS, "Osteoclast formation and differentiation: an overview", J Med Dent Sci, 59, pp.65~74 (2012)
- Lomaga MA, "TRAF6 deficiency results in osteopetrosis and defective interleukin-1, CD40, and LPS signaling", Genes Dev, 13, pp.1015~1024 (1999)[DOI]
- Naito A, "Severe osteopetrosis, defective interleukin-1 signalling and lymph node organogenesis in TRAF6-deficient mice", Genes Cells, 4, pp.353~362 (1999)[DOI]
- Xing L, "Osteoclast fusion and regulation by RANKL-dependent and independent factors", World J Orthop, 3, pp.212~222 (2012)[DOI]
- Yang M, "Osteoclast stimulatory transmembrane protein (OC-STAMP), a novel protein induced by RANKL that promotes osteoclast differentiation", J Cell Physiol, 215, pp.497~505 (2008)[DOI]
- Iwai K, "Abundant expression of tetraspanin CD9 in activated osteoclasts in ovariectomy-induced osteoporosis and in bone erosions of collagen-induced arthritis", Rheumatol Int, 28, pp.225~231 (2008)[DOI]
- Lee SH, "v-ATPase V0 subunit d2-deficient mice exhibit impaired osteoclast fusion and increased bone formation", Nat Med, 12, pp.1403~1409 (2006)[DOI]